Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
May 2020
-
Press release
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years1 Study conclusions are drawn from the largest dataset and… -
Press release
Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation in Europe Phase III… -
Press release
Novartis data highlight benefit of early treatment initiation in patients with secondary progressive multiple sclerosis (SPMS)
Novartis presented a total of 34 abstracts at the Congress of the European Academy of Neurology (EAN), emphasizing its strong multiple sclerosis (MS) portfolio with 20 abstractsLong-term efficacy… -
Statement
Novartis update following WHO Solidarity trial announcement
-
Press release
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
New MONALEESA-7 (M7) and MONALEESA-3 (M3) subgroup analysis to be presented during ASCO20 Virtual Scientific Program Subgroup analysis shows Kisqali plus endocrine therapy extended life… -
Press release
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)
Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achieved no… -
Press release
Novartis study reveals that migraine support in the workspace can significantly decrease the impact of the disease on affected employees
The patients that completed the Migraine Care pilot program reported over 50% reduction in migraine disability and a significant improvement in their patient activation measure after six months … -
Press release
AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
Zolgensma® (onasemnogene abeparvovec) is conditionally approved in Europe for the treatment of patients with spinal muscular atrophy (SMA) and a clinical diagnosis of SMA Type 1; or SMA patients with… -
Press release
Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms
New Kisqali® (ribociclib)* overall survival subgroup analysis in HR+/HER2- advanced breast cancer (ABC) and additional Piqray® (alpelisib) data in patients in HR+/HER2- ABC patients with a PIK3CA… -
Story Discovery
Moving from speculation to science during a pandemic
Florencia Segal’s experiences prepared her to lead the rapid design of a large COVID-19 clinical trial.
-
Ad hoc release
Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14
Tabrecta (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14)…